{"title":"Impact of fibrin in high sensitivity cardiac troponin (Hs-cTn) detection: Implications for quality control","authors":"Chijioke Noris Ezinwa","doi":"10.1016/j.cca.2025.120551","DOIUrl":null,"url":null,"abstract":"<div><div>High-sensitivity troponin (hs-cTn) assays are crucial in the timely diagnosis of acute myocardial infarction (AMI). However, the presence of fibrin clots, among other interfering factors, can lead to false-positive results, undermining diagnostic accuracy. This critical literature review evaluates the implications of fibrin clot detection in hs-cTn testing, emphasising the need for robust quality control measures in emergency cardiac testing. Through this review, it was shown that biomedical scientists must prevent activities during the pre-analysis stage that may lead to fibrin formation. When such situations become inevitable due to various reasons, including patients’ predispositions, several steps were outlined to confirm the diagnostic accuracy of hs-cTn in myocardial infarction. The importance of technological advancements in detecting fibrin and other potential sources of cross-reactivity or interference was also identified through a comparative analysis of some auto-analysers, proposing possible solutions to address these pitfalls as a means of promoting efficiency and quality assurance in the diagnosis of myocardial infarction through high-sensitivity troponin assays. It further exposed the limitations of these digital analysers and how they cannot independently determine the procedural and outcome quality of diagnostic medicine.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120551"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125004309","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
High-sensitivity troponin (hs-cTn) assays are crucial in the timely diagnosis of acute myocardial infarction (AMI). However, the presence of fibrin clots, among other interfering factors, can lead to false-positive results, undermining diagnostic accuracy. This critical literature review evaluates the implications of fibrin clot detection in hs-cTn testing, emphasising the need for robust quality control measures in emergency cardiac testing. Through this review, it was shown that biomedical scientists must prevent activities during the pre-analysis stage that may lead to fibrin formation. When such situations become inevitable due to various reasons, including patients’ predispositions, several steps were outlined to confirm the diagnostic accuracy of hs-cTn in myocardial infarction. The importance of technological advancements in detecting fibrin and other potential sources of cross-reactivity or interference was also identified through a comparative analysis of some auto-analysers, proposing possible solutions to address these pitfalls as a means of promoting efficiency and quality assurance in the diagnosis of myocardial infarction through high-sensitivity troponin assays. It further exposed the limitations of these digital analysers and how they cannot independently determine the procedural and outcome quality of diagnostic medicine.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.